Nature | Why has immunotherapy for brain tumors repeatedly encountered obstacles? The "four aspects" of myeloid cells have been deciphered by researchers
2025.03.05
The field of brain tumor treatment is confronted with a perplexing puzzle: Why does immunotherapy, which has repeatedly achieved remarkable results in other cancers, frequently fail in the treatment of malignant gliomas? A study titled "Programs, origins and immunomodulatory functions of myeloid cells in glioma," published in Nature on February 26th, provides a revolutionary answer. A group of "double agents" has been discovered in the microenvironment of gliomas: myeloid cells, which constitute half of the tumor, carry four distinct genetic programs and repeatedly switch their identities between promoting cancer and combating cancer. These cells may either release inflammatory factors to awaken the immune system or phagocytose anti-cancer signals through scavenger receptors, and they can even transform commonly used hormonal drugs into "accomplices" of immunosuppression.